GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Bentham Science Publishers Ltd.  (3)
  • Pharmacy  (3)
Material
Publisher
  • Bentham Science Publishers Ltd.  (3)
Language
Years
FID
  • Pharmacy  (3)
  • 1
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2021
    In:  Current Pharmaceutical Analysis Vol. 17, No. 10 ( 2021-12), p. 1308-1316
    In: Current Pharmaceutical Analysis, Bentham Science Publishers Ltd., Vol. 17, No. 10 ( 2021-12), p. 1308-1316
    Abstract: Cardiovascular diseases (CVD) have been reported in 8%-16% of patients with 2019 coronavirus disease (COVID-19). Digoxin is one of the main drugs to treat CVD. Objective: The clinician conducted therapeutic drug monitoring (TDM) of digoxin according to the drug usage on patients to monitor the concentration of digoxin, so as to avoid its toxic and side effects, and provide a theoretical reference for clinical usage of digoxin in patients with COVID-19. Methods: A method for quantifying digoxin concentration in plasma with ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) was developed. After simple protein precipitation of plasma with methanol, digoxin and its internal standard (digoxin-d3) were detected in the positive ion mode using multiple reaction monitoring. Results: Plasma digoxin in the range of 0.2-10 ng/mL had good linearity. The UPLC-MS/MS method was validated with inter-run accuracies ranging from 91.3% to 107.4% and precision less than 13%. Nine plasma samples (5 at valley concentration and 4 at follow-up after stopping dosing) from three patients with COVID-19 were tested. The mean plasma digoxin concentration was 0.73 ng/mL (ranged from 0 to 1.31 ng/mL). Digoxin was detected at the concentration of 0.93 ng/mL after stopping drug administration for 14 days. Conclusion: In this study, we established a simple UPLC-MS/MS method using protein-precipitation to perform TDM of digoxin in patients with COVID-19, and found that about 56% of digoxin plasma concentration was within the treatment window (0.8-2.0 ng/mL). Digoxin can be remained in the body for nearly 14 days in severe patients with COVID-19 after stopping dosing.
    Type of Medium: Online Resource
    ISSN: 1573-4129
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2021
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2020
    In:  Combinatorial Chemistry & High Throughput Screening Vol. 22, No. 10 ( 2020-01-16), p. 675-682
    In: Combinatorial Chemistry & High Throughput Screening, Bentham Science Publishers Ltd., Vol. 22, No. 10 ( 2020-01-16), p. 675-682
    Abstract: Blue rubber bleb nevus syndrome (BRBN) or Bean syndrome is a rare Venous Malformation (VM)-associated disorder, which mostly affects the skin and gastrointestinal tract in early childhood. Somatic mutations in TEK have been identified from BRBN patients; however, the etiology of TEK mutation-negative patients of BRBN need further investigation. Method: Two unrelated sporadic BRBNs and one sporadic VM were firstly screened for any rare nonsilent mutation in TEK by Sanger sequencing and subsequently applied to whole-exome sequencing to identify underlying disease causative variants. Overexpression assay and immunoblotting were used to evaluate the functional effect of the candidate disease causative variants. Results: In the VM case, we identified the known causative somatic mutation in the TEK gene c.2740C 〉 T (p.Leu914Phe). In the BRBN patients, we identified two rare germline variants in GLMN gene c.761C 〉 G (p.Pro254Arg) and c.1630G 〉 T(p.Glu544*). The GLMN-P254R-expressing and GLMN-E544X-expressing HUVECs exhibited increased phosphorylation of mTOR-Ser-2448 in comparison with GLMN-WTexpressing HUVECs in vitro. Conclusion: Our results demonstrated that rare germline variants in GLMN might contribute to the pathogenesis of BRBN. Moreover, abnormal mTOR signaling might be the pathogenesis mechanism underlying the dysfunction of GLMN protein.
    Type of Medium: Online Resource
    ISSN: 1386-2073
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2020
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2013
    In:  CNS & Neurological Disorders - Drug Targets Vol. 11, No. 8 ( 2013-01-01), p. 1045-1051
    In: CNS & Neurological Disorders - Drug Targets, Bentham Science Publishers Ltd., Vol. 11, No. 8 ( 2013-01-01), p. 1045-1051
    Type of Medium: Online Resource
    ISSN: 1871-5273
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2013
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...